Citations

Clear

219 citation(s) found for "Do, Ron".

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study
Hashmi, Shahrukh K. , Musso, Maurizio , Uzay, Ant , Langmuir, Peter, Li, Xuechan, Gowda, Maanasa, Stefanelli, Tommaso , Zeiser, Robert , Russo, Domenico , Ram, Ron , Chakraverty, Ronjon , Middeke, Jan Moritz , Giebel, Sebastian , Hamad, Nada , Lee, Stephanie J. , Teshima, Takanori , Locatelli, Franco

Mayo Clinic

Blood | December 1, 2023 | Volume: 142 | Issue: Supplement 1 | Pages: 654-654

10.1182/blood-2023-172590 Get It

Introduction: Corticosteroids (CS) are the standard first-line treatment for patients (pts) with chronic graft-versus-host disease (cGvHD), but pts can be unresponsive or become refractory to or dependent on CS (SR/D).Ruxolitinib (RUX), a JAK1/2 inhibitor, is approved for the treatment of pts ≥12 years of age with SR/D-cGVHD, based on the primary outcomes from the randomized, phase III REACH3 (NCT03112603) study, which demonstrated the superior efficacy of RUX vs best available treatment (BAT) in pts with SR/D-cGVHD. Here, we present the final, long-term efficacy and safety outcomes from REACH3. Methods: Pts ≥12 years of age with moderate or severe SR/D-cGVHD were randomized 1:1 to receive either RUX 10 mg twice daily (BID) or investigator-selected BAT and followed for 3 years, till discontinuation or death. The primary analysis was conducted at week 24 (Cycle 7 Day 1 [C7D1]) in randomized pts, then pts entered the extension period (C7-39) in which they continued treatment, switched from BAT to RUX (crossover cohort), or discontinued treatment and entered long-term survival follow-up (FU). Failure-free survival (FFS; key secondary endpoint), duration of response (DOR), overall survival (OS), non-relapse mortality (NRM), malignancy relapse (MR), and safety were analyzed at 3 years (week 156; final data cut off 15 Dec 2022). Overall response rate (ORR) and best overall response (BOR) during the crossover treatment period were analyzed for pts who switched from BAT to RUX on or after C7D1. Results: Of 329 pts randomized, 53 completed the treatment period and 276 discontinued, 115 entered survival FU (RUX: 73/165; BAT:42/164); 70 pts crossed over from BAT to RUX of which 16 completed the crossover treatment period and 24 entered survival FU. Median FFS was longer in the RUX vs BAT arms (38.4 vs 5.7 months; hazard ratio [HR]=0.361, 95% confidence interval [CI]: 0.268, 0.485) with 12-month FFS probabilities of 64.0% (95% CI: 56.1, 70.8) and 28.8% (95% CI: 21.8, 36.1), respectively. Median OS was not reached and there was no difference in risk of death between the arms (HR=0.851, 95% CI: 0.544, 1.331) [Table 1]. Median DOR was 6.4 months (95% CI: 4.9, 11.4) in the BAT arm but was not reached for the RUX arm; notably, the probability of maintaining DOR at 3 years was higher in RUX (59.6%; 95% CI: 50.4, 67.6) vs BAT (26.7%; 95% CI: 18.5, 35.5). NRM event rates were similar between the arms (RUX: 29/165; BAT 34/164), and MR events were similar and low in both arms (13/156 and 11/160, RUX and BAT respectively) up to 3 years. The ORR at week 24 after crossover from BAT to RUX was 50.0% (95% CI: 37.8, 62.2), including complete response (CR) in 4 (5.7%) pts and partial response (PR) in 31 (44.3%) pts. The BOR during crossover was 81.4% (95% CI: 70.3, 89.7), including CR of 7.1% and PR of 74.3%; disease progression only occurred in 1 pt. Almost all pts treated during the main treatment period (RUX: 100%; BAT: 93.7%) experienced ≥1 adverse event (AE) and, in general, AE rates were higher in the RUX vs BAT arms [Table 2], likely due to prolonged FU and exposure to RUX (median exposure to treatment of 52.9 weeks vs. 24.1 weeks for RUX and BAT, respectively).Anemia was the most common AE (RUX: 33.9%; BAT: 15.8%) and grade ≥3 AE for RUX (17.6% vs BAT 9.5%, respectively); grade ≥3 neutropenia, thrombocytopenia, alanine aminotransferase increase, and gamma-glutamyltransferase increase were also ≥5% higher for RUX than BAT. Anemia (24.2%; grade ≥3, 10.3%) and thrombocytopenia (3.8%) were the most common RUX and BAT treatment-related AEs, respectively. Infections, excluding tuberculosis, were the most common AE of special interest (77.6% vs. 68.4%; grade ≥3, 31.5% and 26.6%, for RUX and BAT, respectively). On-treatment deaths were mainly due to cGvHD (n/N, RUX: 10/18; BAT 6/12). Conclusions: After 3 years of treatment in REACH3, the longer FFS and higher DOR with RUX vs BAT indicated that cGVHD was more in control with RUX treatment. Notably, efficacy was demonstrated in pts who switched from BAT to RUX with an ORR similar to that in pts randomized to RUX. RUX was well tolerated with no unexpected toxicities and safety that was consistent with earlier studies. Overall, the long-term control of cGVHD and tolerability of RUX was demonstrated for pts ≥12 years of age with SR/D-cGvHD.
Long‐term overall survival in patients undergoing liver resection for metastatic anal squamous cell carcinoma
Lo, Winifred , Ferrone, Cristina R. , Nebbia, Martina , Pery, Ron, Steel, Jennifer L. , Tohme, Samer , Lo, Winifred M , Cleary, Sean, Dogeas, Epameinondas , Etherington, Mark S. , Cleary, Sean P. , Geller, David A.

Mayo Clinic

Journal of Surgical Oncology | November 29, 2023 | Volume: 129 | Issue: 3 | Pages: 568-573

10.1002/jso.27539 | PMID 38018352 Get It

AbstractBackground and ObjectivesThere is limited research on management of metastatic anal canal squamous cell carcinoma (SCC) to the liver. This study aimed to describe outcomes for patients undergoing liver resection of anal SCC metastases.MethodsA multicenter, retrospective cohort study was conducted by three tertiary‐referral centers. Patients undergoing liver surgery between 2008 and 2022 were included. Cox regression analysis was performed to evaluate predictors of recurrence and survival and Kaplan–Meier analysis was performed for 1‐, 3‐, and 5‐year survival.ResultsTwenty‐one patients underwent liver resection and/or ablation. None were HIV positive and 24% had known HPV infection. 20/21(95%) patients had undergone Nigro protocol for management of the primary tumor with 12/21 (57%) patients experiencing complete response. 4/21 (19%) patients had synchronous liver metastases at time of diagnosis. Median tumor size was 5.0 cm and median tumor number was one. At analysis, 52% remained alive. Median overall survival was 32.2 months. 5‐year overall survival was 50%. Median recurrence‐free survival was 7.7 months and 5‐year recurrence‐free survival was 30%. Need for salvage abdominoperineal resection was negatively associated with recurrence‐free survival. The most common site of recurrence was the liver.ConclusionsLiver resection for metastatic anal SCC can be beneficial for appropriately selected patients.
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugs
Nijenhuis, Marga , Manson, Lisanne E. N. , Soree, Bianca, Boer-Veger, Nienke de, Buunk, Anne M. , Houwink, Elisa J. F. , Risselada, Arne, Rongen, Gerard A. , Schaik, Ron HN van , Swen, Jesse J. , Westrhenen, Roos van , Deneer, Vera H.M. , Houwink, Elisa J F , Boer‐Veger, Nienke J. de, Touw, Daan Johannes , Guchelaar, Henk‐Jan

Mayo Clinic

No container title available | November 8, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3255043/v1 Get It

Abstract The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx implementation by developing evidence-based pharmacogenetics guidelines to optimize pharmacotherapy. This guideline describes the gene-drug interaction of CYP2C9 and HLA-B with phenytoin, HLA-A and HLA-B with carbamazepine and HLA-B with oxcarbazepine and lamotrigine. A systematic review was performed and pharmacotherapeutic recommendations were developed. For CYP2C9 intermediate and poor metabolisers, the DPWG recommends lowering the daily dose of phenytoin and adjust based on effect and serum concentration after 7–10 days. For HLA-B*15:02 carriers, the risk of severe cutaneous adverse events associated with phenytoin, carbamazepine, oxcarbazepine and lamotrigine is strongly increased. For carbamazepine, this risk is also increased in HLA-B*15:11 and HLA-A*31:01 carriers. For HLA-B*15:02, HLA-B*15:11 and HLA-A*31:01 positive patients, the DPWG recommends choosing an alternative anti-epileptic drug. If not possible, it is recommended to advise the patient to report any rash while using carbamazepine, lamotrigine, oxcarbazepine or phenytoin immediately. Carbamazepine should not be used in an HLA-B*15:02 positive patient. DPWG considers CYP2C9 genotyping before the start of phenytoin “essential” for toxicity prevention. For patients with an ancestry in which the abovementioned HLA-alleles are prevalent, the DPWG considers HLA-B*15:02 genotyping before the start of carbamazepine, phenytoin, oxcarbazepine and lamotrigine “beneficial”, as well as genotyping for HLA-B*15:11 and HLA-A*31:01 before initiating carbamazepine.
The Human Phenotype Ontology in 2024: phenotypes around the world
Gargano, Michael , Matentzoglu, Nicolas , Coleman, Ben , Addo-Lartey, Eunice B, Anagnostopoulos, Anna V. , Anderton, Joel , Avillach, Paul , Bagley, Anita , Bakštein, Eduard , Balhoff, James P. , Baynam, Gareth , Bertram, Holli , Bishop, Somer , Bodenstein, David F. , Botas, Pablo , Cady, J , Cameron, Rhiannon , Castellanos, F , Chan, Lauren , Cruz-Rojo, Jaime , Dahan‐Oliel, Noémi , Davids, Jon R. , Dieuleveult, Maud de , Souza, Vinícius de , Vries, Bert B.A. de , Diaz‐Byrd, Claudia , Duyzend, Michael , Elfeky, Reem , Essaid, Shahim , Fabrizzi, Carolina , Freudenberg‐Hua, Yun , Gabriel, Davera , Moses, Rachel Gore , Green, Ian, Gu, Weihong, Guthrie, Julia, Hamosh, Ada , Hanauer, Marc , Hanušová, Kateřina , He, Yongqun , Helbig, Ingo , Huang, Shangzhi, Joseph, Lisa , Keramatian, Kamyar , King, Bryan , Knoflach, Katrin , Koolen, David A. , Kraus, Megan L , Kroll, Carlo , Kusters, Maaike , Ladewig, Markus S. , Lagorce, David , Laraway, Bryan , Li, Xiarong, Lucano, Caterina , Marazita, Mary L. , Martínez‐Glez, Víctor , McHenry, Toby H, McInnis, Melvin G. , Mihulová, Michaela , Millett, Caitlin E. , Moslerová, Veronika , Narutomi, Kenji, Nevado, Julián , Nierenberg, Andrew A. , Čajbiková, Nikola Novák , Ogishima, Soichi , Olson, Daniel , Ortiz, Abigail, Nanclares, Guiomar Pérez de , Peters, Amy T. , Rapp, Christina , Rath, Ana , Rekerle, Lauren , Roberts, Angharad M. , Roy, Suzy, Sanders, Stephan , Schuetz, Catharina , Schwarz, Martin , Scott, Katie , Seelow, Dominik , Seitz, Berthold , Shen, Yiping , Similuk, Morgan , Simon, Eric S. , Singh, Balwinder , Smith, Cynthia L. , Smolinsky, Jake T , Stafford, Elizabeth , Stefancsik, Ray , Steinhaus, Robin , Strawbridge, Rebecca , Sundaramurthi, Jagadish Chandrabose , Talapova, Polina , Castano, Jair A Tenorio , Tesner, Pavel , Thomas, Rhys H. , Turnovec, Marek , Gijn, Mariëlle van , Vlčková, Markéta , Walden, Anita , Ware, James S. , Wiafe, Addo A, Wiafe, Samuel Agyei , Wiggins, Lisa D. , Williams, Andrew E. , Wu, Chen , Xiong, Hui, Yalın, Nefize , Yamamoto, Yasunori , Yatham, Lakshmi N. , Yocum, Anastasia K. , Young, Allan H. , Yüksel, Zafer , Zandi, Peter P. , Zvolský, Miroslav , Carmody, Leigh , Harris, Nomi L. , Muñoz-Torres, Mónica , Daniš, Daniel , Mungall, Chris , Haendel, Melissa , Robinson, Peter N. , Gargano, Michael A , Bagley, Anita M , Bello, Susan M , Berk, Michael , Bertram, Holli , Bishop, Somer , Blau, Hannah , Bodenstein, David F , Botas, Pablo , Boztug, Kaan , Čady, Jolana , Callahan, Tiffany J , Cameron, Rhiannon , Carbon, Seth J , Castellanos, Francisco , Caufield, J Harry , Chan, Lauren E , Chute, Christopher G , Cruz-Rojo, Jaime , Dahan-Oliel, Noémi , Davids, Jon R , de Dieuleveult, Maud , de Vries, Bert B A , de Vries, Esther , DePaulo, J Raymond , Derfalvi, Beata , Dhombres, Ferdinand , Diaz-Byrd, Claudia , Dingemans, Alexander J M , Donadille, Bruno , Duyzend, Michael , Elfeky, Reem , Essaid, Shahim , Fabrizzi, Carolina , Fico, Giovanna , Firth, Helen V , Freudenberg-Hua, Yun , Fullerton, Janice M , Gilmour, Kimberly , Giordano, Jessica , Goes, Fernando , Moses, Rachel Gore , Griese, Matthias , Groza, Tudor , Guthrie, Julia , Gyori, Benjamin , Hamosh, Ada , Hanauer, Marc , Hanušová, Kateřina , He, Yongqun , Hegde, Harshad , Helbig, Ingo , Holasová, Kateřina , Hoyt, Charles Tapley , Hurwitz, Eric , Jacobsen, Julius O B , Joseph, Lisa , Keramatian, Kamyar , King, Bryan , Knoflach, Katrin , Koolen, David A , Kraus, Megan L , Kusters, Maaike , Ladewig, Markus S , Lagorce, David , Lai, Meng-Chuan , Lapunzina, Pablo , Laraway, Bryan , Lewis-Smith, David , Lucano, Caterina , Majd, Marzieh , Marazita, Mary L , Martinez-Glez, Victor , McInnis, Melvin G , McMurry, Julie A , Mihulová, Michaela , Millett, Caitlin E , Mitchell, Philip B , Moslerová, Veronika , Nematollahi, Shahrzad , Nevado, Julian , Nierenberg, Andrew A , Čajbiková, Nikola Novák , Nurnberger, John I , Ogishima, Soichi , Olson, Daniel , Ortiz, Abigail , Pachajoa, Harry , Perez de Nanclares, Guiomar , Peters, Amy T , Putman, Tim , Rath, Ana , Reese, Justin , Rekerle, Lauren , Sanders, Stephan J , Schuetz, Catharina , Schulte, Eva , Schulze, Thomas , Schwarz, Martin , Scott, Katie , Seelow, Dominik , Seitz, Berthold , Similuk, Morgan N , Simon, Eric S , Singh, Balwinder , Smedley, Damian , Smith, Cynthia L , Smolinsky, Jake T , Sperry, Sarah , Stafford, Elizabeth , Stefancsik, Ray , Steinhaus, Robin , Strawbridge, Rebecca , Sundaramurthi, Jagadish Chandrabose , Talapova, Polina , Tenorio Castano, Jair A , Tesner, Pavel , Thomas, Rhys H , Thurm, Audrey , Turnovec, Marek , van Gijn, Marielle E , Vasilevsky, Nicole A , Vlčková, Markéta , Walden, Anita , Wang, Kai , Wapner, Ron , Ware, James S , Wiafe, Samuel A , Wiggins, Lisa D , Williams, Andrew , Wyrwoll, Margot J , Yalin, Nefize , Yamamoto, Yasunori , Yatham, Lakshmi N , Yocum, Anastasia K , Young, Allan H , Yüksel, Zafer , Zandi, Peter P , Zankl, Andreas , Zarante, Ignacio , Zvolský, Miroslav , Toro, Sabrina , Carmody, Leigh C , Harris, Nomi L , Munoz-Torres, Monica C , Danis, Daniel , Mungall, Christopher J , Köhler, Sebastian , Haendel, Melissa , Robinson, Peter N , Berk, Michael , Chute, Christopher G. , Fico, Giovanna , Fullerton, Janice M. , Giordano, Jessica L. , Jiang, Xiaofeng , Lai, Meng‐Chuan , Schulte, Eva C. , Smedley, Damian , Sperry, Sarah H. , Xiong, Hui

Mayo Clinic

Nucleic Acids Research | October 19, 2023 | Volume: 52 | Issue: D1 | Pages: D1333-D1346

10.1093/nar/gkad1005 | PMID 37953324 Get It

Abstract The Human Phenotype Ontology (HPO) is a widely used resource that comprehensively organizes and defines the phenotypic features of human disease, enabling computational inference and supporting genomic and phenotypic analyses through semantic similarity and machine learning algorithms. The HPO has widespread applications in clinical diagnostics and translational research, including genomic diagnostics, gene-disease discovery, and cohort analytics. In recent years, groups around the world have developed translations of the HPO from English to other languages, and the HPO browser has been internationalized, allowing users to view HPO term labels and in many cases synonyms and definitions in ten languages in addition to English. Since our last report, a total of 2239 new HPO terms and 49235 new HPO annotations were developed, many in collaboration with external groups in the fields of psychiatry, arthrogryposis, immunology and cardiology. The Medical Action Ontology (MAxO) is a new effort to model treatments and other measures taken for clinical management. Finally, the HPO consortium is contributing to efforts to integrate the HPO and the GA4GH Phenopacket Schema into electronic health records (EHRs) with the goal of more standardized and computable integration of rare disease data in EHRs.
The Quality of Discharge Summaries After Acute Kidney Injury
Giles, C. , Novakovic, Milica, Frazee, Erin N. , Beaubien‐Souligny, William , Birks, Peter , Neyra, Javier A. , Silver, Samuel A. , Giles, Cameron , Frazee, Erin N , Beaubien-Souligny, William , Silver, Samuel A , Hopman, Wilma M. , Wald, Ron

Mayo Clinic

Canadian Journal of Kidney Health and Disease | September 28, 2023 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/20543581231199018 | PMID 37781153 Get It

Background: Acute kidney injury (AKI) increases the risk of hospital readmission, chronic kidney disease, and death. Therefore, effective communication in discharge summaries is essential for safe transitions of care. Objective: The objectives of this study were to determine the quality of discharge summaries in AKI survivors and identify predictors of higher quality discharge summaries. Design: Retrospective chart review. Setting: Tertiary care academic center in Ontario, Canada. Patients: We examined the discharge summary quality of 300 randomly selected adult patients who survived a hospitalization with AKI at our tertiary care hospital, stratified by AKI severity. We included 150 patients each from 2015 to 2016 and 2018 to 2019, before and after introduction of a post-AKI clinic in 2017. Measurements: We reviewed charts for 9 elements of AKI care to create a composite score summarizing discharge summary quality. Methods: We used multivariable logistic regression to identify predictors of discharge summary quality. Results: The median discharge summary composite score was 4/9 (interquartile range, 2-6). The least frequently mentioned elements were baseline creatinine (n = 55, 18%), AKI-specific follow-up labs (n = 66, 22%), and medication recommendations (n = 80, 27%). The odds of having a higher quality discharge summary (composite score ≥4/9) was greater for every increase in baseline creatinine of 25 μmol/L (adjusted odds ratio [aOR]: 1.27; 95% confidence interval [CI]: 1.03, 1.56), intrarenal etiology (aOR: 2.32; 95% CI: 1.26, 4.27), and increased AKI severity (stage 2 aOR: 2.57; 95% CI: 1.35, 4.91 and stage 3 aOR: 3.36; 95% CI: 1.56, 7.22). There was no association between discharge summary quality and the years before and after introduction of a post-AKI clinic (aOR: 0.77; 95% CI: 0.46, 1.29). Limitations: The single-center study design limits generalizability. Conclusions: Most discharge summaries are missing key AKI elements, even in patients with severe AKI. These gaps suggest several opportunities exist to improve discharge summary communication following AKI.
Minimum 10-Year Clinical Outcomes and Survivorship of Meniscal Allograft Transplantation With Fresh-Frozen Allografts Using the Bridge-in-Slot Technique
Cotter, Eric J. , Gilat, Ron , Meeker, Zachary D. , Frazier, Landon P., Yanke, Adam B. , Cole, Brian J. , Wagner, Kyle R. , Kaiser, Joshua T. , Hevesi, Mario , Frazier, Landon P.

Mayo Clinic

The American Journal of Sports Medicine | August 18, 2023 | Volume: 51 | Issue: 11 | Pages: 2954-2963

10.1177/03635465231188657 | PMID 37594374 Get It

Background: Meniscal allograft transplantation (MAT) has been shown to provide clinical benefits in patients with symptomatic meniscal deficiency in the short term and midterm. There is, however, a paucity of data regarding long-term outcomes after MAT using fresh-frozen allografts and the bridge-in-slot technique. Purpose: To report clinical outcomes and revision rates after primary MAT with fresh-frozen allografts and the bridge-in-slot technique in a large case series of patients at a 10-year minimum follow-up. Study Design: Case series; Level of evidence, 4. Methods: A retrospective review of prospectively collected data was performed on patients undergoing primary MAT between 2001 and 2012. Lysholm, International Knee Documentation Committee subjective form, and Knee injury and Osteoarthritis Outcome Score subscales were collected preoperatively and at 1-, 2-, 5-, and minimum 10-year follow-ups. Cox proportional hazards modeling was used to identify variables associated with reoperation and failure, defined as revision MAT or conversion to arthroplasty. Reoperation was defined as a subsequent surgical intervention on the transplanted meniscus, including partial or total meniscectomy, meniscal repair, or failure as defined in the previous sentence. Results: A total of 174 patients undergoing MAT met the inclusion criteria and were followed for a mean of 12.7 ± 2.7 years (range, 10.0-21.0 years). The mean age at surgery was 28.3 ± 10.1 years. The patients were predominantly female (n = 92; 53%), and medial MAT was the most commonly performed procedure (n = 91; 52%). Concomitant procedures were performed in 115 patients (66%), with the most common procedure being osteochondral allograft transplantation (n = 59; 34%). Patients demonstrated statistically significant postoperative improvements at all time points for all patient-reported outcome measures ( P ≤ .0001). A total of 65 patients (37%) underwent a meniscal reoperation at a mean time of 6.6 ± 5.5 years (range, 0.3-16.7 years) postoperatively. A total of 40 patients (23%) met the criteria for failure at a mean time of 7.3 ± 5.0 years (range, 1.0-17.4 years) after MAT, with 22 of these patients having undergone a previous meniscal reoperation. At the final follow-up, 13 patients (7%) had undergone revision MAT and 27 (15%) had converted to arthroplasty. The MAT survival rates free of meniscal reoperation and failure were 73% and 85% at 10 years and 60% and 72% at 15 years, respectively. At the time of the final follow-up, 86% of patients reported that they were satisfied with their overall postoperative condition. Conclusion: Primary MAT demonstrates efficacy and durability with high rates of patient satisfaction at a minimum 10-year follow-up. Patients should be counseled that although reoperation rates may approach 40% at 15 years, rates of overall revision MAT and conversion to arthroplasty remain low at long-term follow-up.
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel
Yerushalmi, Rinat , Yablonski‐Peretz, Tamar, Wang, Qin , Bolla, Manjeet K. , Michailidou, Kyriaki , Ahearn, Thomas U. , Andrulis, Irene L. , Antoniou, Antonis C. , Auvinen, Päivi , Freeman, Laura Beane, Beckmann, Matthias W. , Bermisheva, Marina , Bodelón, Clara , Bogdanova, Natalia , Bojesen, Stig E. , Byers, Helen, Camp, Nicola J. , Chang‐Claude, Jenny , Chirlaque, María‐Dolores , Collaborators, NBCS, Collée, Margriet J., Dörk, Thilo , Eccles, Diana , Evans, D. Gareth , Fasching, Peter A. , Flyger, Henrik, García‐Closas, Montserrat , Goldberg, Mark S. , Guénel, Pascal , Hamann, Ute, He, Wei , Hillemanns, Peter , Hoppe, Reiner , Hopper, John L. , Investigators, ABCTB, Jakovchevska, Simona, John, Esther M. , Johnson, Nichola , Jones, Michael E. , Kristensen, Vessela N. , Kurian, Allison W. , Lambrechts, Diether , Lejbkowicz, Flavio, Lindblom, Annika , Loibl, Sibylle , Lori, Adriana , Mannermaa, Arto, Manoochehri, Mehdi, Mavroudis, Dimitrios, Menon, Usha , Nevelsteen, Ines, Obi, Nadia , Offit, Ken, Plaseska‐Karanfilska, Dijana , Park‐Simon, Tjoung‐Won , Patel, Alpa V. , Rack, Brigitte , Rhenius, Valerie , Romero, Atocha , Schwentner, Lukas , Shah, Mitul , Stone, Jennifer , Taylor, Jack A. , Kolk, Lizet E. van der, Wendt, Camilla, Yang, Xiaohong R. , Zheng, Wei , Pharoah, Paul D.P. , Easton, Douglas F. , Ben-Sachar, Shay, Elefant, Naama , Shamir, Ron , Elkon, Ran , Lambrechts, Diether , Michailidou, Kyriaki , Antoniou, Antonis C , Devilee, Peter , Eccles, Diana , Newman, William G , Radice, Paolo , Elkon, Ran , Dörk, Thilo , Lambrechts, Diether , Hillemanns, Peter , Pharoah, Paul D P , Menon, Usha , Evans, D Gareth , John, Esther M , Jones, Michael E , Lambrechts, Diether , Guénel, Pascal , Romero, Atocha , García-Closas, Montserrat , Bogdanova, Natalia V , Taylor, Jack A , Zheng, Wei , Kurian, Allison W , Stone, Jennifer , Bojesen, Stig E , Lindblom, Annika , Plaseska-Karanfilska, Dijana , Levi, Hagai , Carmi, Shai , Rosset, Saharon , Zick, Aviad , Dennis, Joe , Lush, Michael J. , Anton‐Culver, Hoda , Arndt, Volker , Augustinsson, Annelie , Behrens, Sabine , Brenner, Hermann , Castelao, Jose E. , Chung, Wendy K. , Clarke, Christine L. , Collaborators, NBCS, Collée, Margriet , Colonna, Sarah V. , Couch, Fergus J. , Cox, Angela , Cross, Simon S. , Czene, Kamila , Daly, Mary Beryl , Devilee, Peter , Dossus, Laure , Eliassen, A. Heather , Eriksson, Mikael , Fletcher, Olivia , Fritschi, Lin , Gabrielson, Marike , Gago-Domínguez, Manuela , García-Sáenz, José Á. , Genkinger, Jeanine M. , Giles, Graham G. , Hall, Per N , Hollestelle, Antoinette , Investigators, ABCTB, Jakubowska, Anna , Jernström, Helena , Vijai, Joseph , Kaaks, Rudolf , Хуснутдинова, Э. К. , Kitahara, Cari M. , Koutros, Stella , Lacey, James V. , Marchand, Loı̈c Le , Lubiński, Jan , Mannermaa, Arto, Mulligan, Anna Marie , Murphy, Rachel A. , Newman, William G. , O’Brien, Katie M. , Olshan, Andrew F. , Olson, Janet E. , Panico, Salvatore , Peterlongo, Paolo , Radice, Paolo , Rennert, Gad , Saloustros, Emmanouil , Sandler, Dale P. , Schmidt, Marjanka K. , Sharma, Priyanka , Simard, Jacques , Southey, Melissa C. , Tapper, William , Teras, Lauren R. , Toland, Amanda Ewart , Troester, Melissa A. , Truong, Thérèse , Weinberg, Clarice R. , Ziogas, Argyrios , Dunning, Alison M.

Mayo Clinic

Journal of Medical Genetics | July 14, 2023 | Volume: 60 | Issue: 12 | Pages: 1186-1197

10.1136/jmg-2023-109185 | PMID 37451831 Get It

Background Polygenic risk score (PRS), calculated based on genome-wide association studies (GWASs), can improve breast cancer (BC) risk assessment. To date, most BC GWASs have been performed in individuals of European (EUR) ancestry, and the generalisation of EUR-based PRS to other populations is a major challenge. In this study, we examined the performance of EUR-based BC PRS models in Ashkenazi Jewish (AJ) women. Methods We generated PRSs based on data on EUR women from the Breast Cancer Association Consortium (BCAC). We tested the performance of the PRSs in a cohort of 2161 AJ women from Israel (1437 cases and 724 controls) from BCAC (BCAC cohort from Israel (BCAC-IL)). In addition, we tested the performance of these EUR-based BC PRSs, as well as the established 313-SNP EUR BC PRS, in an independent cohort of 181 AJ women from Hadassah Medical Center (HMC) in Israel. Results In the BCAC-IL cohort, the highest OR per 1 SD was 1.56 (±0.09). The OR for AJ women at the top 10% of the PRS distribution compared with the middle quintile was 2.10 (±0.24). In the HMC cohort, the OR per 1 SD of the EUR-based PRS that performed best in the BCAC-IL cohort was 1.58±0.27. The OR per 1 SD of the commonly used 313-SNP BC PRS was 1.64 (±0.28). Conclusions Extant EUR GWAS data can be used for generating PRSs that identify AJ women with markedly elevated risk of BC and therefore hold promise for improving BC risk assessment in AJ women.
Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma
Levin, Solomon , Tomasini, Michael D. , Knox, James , Shirani, Mahsa , Shebl, Bassem , Requena, David , Clark, Jackson, Heissel, Søren , Alwaseem, Hanan , Surjan, Rodrigo C. , Lahasky, Ron, Molina, Henrik , Lyons, Barbara A. , Migler, Rachael D. , Levin, Solomon N , Surjan, Rodrigo , Torbenson, Michael S , Lyons, Barbara , Migler, Rachael D , Coffino, Philip , Simon, Sanford M , Requena, David , Torbenson, Michael , Simon, Sanford M.

Mayo Clinic

Science Advances | June 21, 2023 | Volume: 9 | Issue: 25 | Pages: No page available

10.1126/sciadv.adg7038 | PMID 37343102 Get It

Fibrolamellar hepatocellular carcinoma (FLC) is a usually lethal primary liver cancer driven by a somatic dysregulation of protein kinase A. We show that the proteome of FLC tumors is distinct from that of adjacent nontransformed tissue. These changes can account for some of the cell biological and pathological alterations in FLC cells, including their drug sensitivity and glycolysis. Hyperammonemic encephalopathy is a recurrent problem in these patients, and established treatments based on the assumption of liver failure are unsuccessful. We show that many of the enzymes that produce ammonia are increased and those that consume ammonia are decreased. We also demonstrate that the metabolites of these enzymes change as expected. Thus, hyperammonemic encephalopathy in FLC may require alternative therapeutics.
A Synchronous Robotic Resection of Colorectal Cancer and Liver Metastases—Our Initial Experience
Rudnicki, Yaron , Pery, Ron, Shawki, Sherief , Cleary, Sean Patrick, Warner, Susanne G. , Cleary, Sean P. , Behm, Kevin T.

Mayo Clinic

Journal of Clinical Medicine | May 3, 2023 | Volume: 12 | Issue: 9 | Pages: 3255

10.3390/jcm12093255 | PMID 37176695 Get It

Introduction: Synchronous robotic colorectal and liver resection for metastatic colorectal cancer (mCRC) is gaining popularity. This case series describes our initial institutional experience. Methods: A retrospective study of synchronous robotic colorectal and liver resections for metastatic colorectal cancer (March 2020 to December 2021). Results: Eight patients underwent synchronous robotic resections. The median age was 59 (45–72), and the median body mass index was 29 (20–33). Seven received neoadjuvant chemotherapy, and five rectal cancers received neoadjuvant radiotherapy. One patient had a low anterior resection with major hepatectomy, two had low anterior resection with minor hepatectomy, and one had abdominoperineal resection with major hepatectomy. One patient had a left colectomy with minor hepatectomy, and two had right colectomies with minor hepatectomy. We used five robotic 8/12 mm ports in all cases. Extraction incisions were Pfannenstiel in four patients, colostomy site in two patients, one perineal incision, and one supra-umbilical incision. The median estimated blood loss was 200 mL (25–500), and the median operative time was 448 min (374–576). There were no intra-operative complications or conversions. Five patients had the liver resection first, and two of six anastomoses were performed before the liver resection. The Median length of stay was 4 days (3–14). There were two post-operative complications, prolonged ileus and DVT, with a Clavien-Dindo complication grade of I and II, respectively. There were no readmissions or reoperations. All colorectal and liver resection margins were negative. Conclusions: Synchronous robotic colorectal and liver resection can be performed effectively utilizing one port configuration with acceptable short-term outcomes and quality of oncologic resection.
Serially measured high-sensitivity cardiac troponin T, N-terminal-pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and growth differentiation factor 15 for risk assessment after acute coronary syndrome: the BIOMArCS cohort
Gürgöze, Muhammed T. , Akkerhuis, K. Martijn , Umans, Victor A. , Kietselaer, Bas , Schotborgh, Carl E. , Lenderink, Timo , Aksoy, Ismail , Harst, Pim van der , Asselbergs, Folkert W. , Maas, Arthur , Ophuis, Anton J. Oude, Krenning, Boudewijn J., Winter, Robbert J. de , The, Salem H.K., Wardeh, Alexander J. , Hermans, Walter, Cramer, G. Etienne , Gorp, Ina van, Schaik, Ron H. N. van , Boersma, Eric , Lenderink, Timo , Boersma, Eric , van der Harst, Pim , Kietselaer, Bas L J H , Oemrawsingh, Rohit M. , Ronner, Eelko , de Rijke, Yolanda B

Mayo Clinic

European Heart Journal: Acute Cardiovascular Care | April 25, 2023 | Volume: 12 | Issue: 7 | Pages: 451-461

10.1093/ehjacc/zuad042 | PMID 37096818 Get It

Abstract Aims Evidence regarding the role of serial measurements of biomarkers for risk assessment in post-acute coronary syndrome (ACS) patients is limited. The aim was to explore the prognostic value of four, serially measured biomarkers in a large, real-world cohort of post-ACS patients. Methods and results BIOMArCS is a prospective, multi-centre, observational study in 844 post-ACS patients in whom 12 218 blood samples (median 17 per patient) were obtained during 1-year follow-up. The longitudinal patterns of high-sensitivity cardiac troponin T (hs-cTnT), N-terminal-pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), and growth differentiation factor 15 (GDF-15) were analysed in relation to the primary endpoint (PE) of cardiovascular mortality and recurrent ACS using multivariable joint models. Median age was 63 years, 78% were men and the PE was reached by 45 patients. The average biomarker levels were systematically higher in PE compared with PE-free patients. After adjustment for 6-month post-discharge Global Registry of Acute Coronary Events score, 1 standard deviation increase in log[hs-cTnT] was associated with a 61% increased risk of the PE [hazard ratio (HR) 1.61, 95% confidence interval (CI) 1.02–2.44, P = 0.045], while for log[GDF-15] this was 81% (HR 1.81, 95% CI 1.28–2.70, P = 0.001). These associations remained significant after multivariable adjustment, while NT-proBNP and hs-CRP were not. Furthermore, GDF-15 level showed an increasing trend prior to the PE (Structured Graphical Abstract). Conclusion Longitudinally measured hs-cTnT and GDF-15 concentrations provide prognostic value in the risk assessment of clinically stabilized patients post-ACS. Clinical Trial Registration The Netherlands Trial Register. Currently available at URL https://trialsearch.who.int/; Unique Identifiers: NTR1698 and NTR1106.